Silverstein appointed Chief Financial Officer at Artios Pharma

09 Feb, 2024
Tony Quested
The best of Cambridge UK life science businesses are making encouraging headway commercially in the US and Artios Pharma’s latest move looks set to provide another ‘wow’ moment on both sides of the Pond.
Christine Silverstein. Image courtesy of Artios Pharma.

Artios has just hired biopharma industry class act Christine Silverstein as Chief Financial Officer. As CEO Niall Martin remarks, her track record of raising capital, preparing companies for IPO and experience with partnerships and M & A will position Artios for success as it continues to advance its leading DNA damage response (DDR) pipeline.

Christine will play a key leadership role in the United States for Artios which has UK offices at Babraham Research Campus in Cambridge and a US subsidiary in New York.

Artios is on a mission to kill cancer by exploiting DDR and repair pathways that are leveraged by cancer cells to promote their survival. Its specialised DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR.

The company has built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications – and it has strategic partnerships with Merck KGaA and Novartis plus research collaborations with premiere institutions like Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute.

Before joining Artios, Christine most recently held executive leadership roles at Excision Biotherapeutics, Inc. and Emendo Biotherapeutics, where she led financial strategy and corporate partnering, improved operational efficiency and facilitated substantial growth.

She said: “As recognised innovators in DDR drug discovery, Artios’ advanced pipeline targeting the DNA damage response offers cutting-edge approaches for difficult-to-treat cancers.

“I am excited to join Artios at this pivotal time, with clinical data expected for lead programs including ATR inhibitor ART0380 and novel Pol theta inhibitor ART6043 over the next 12 months.

“I look forward to partnering with the Artios team as we approach this next stage of growth and work to advance potentially life-extending therapies for the treatment of a broad range of solid tumours.”

Christine has more than 15 years of financial leadership experience spanning strategic and operational roles across both private and public biopharma companies.

As CFO of Emendo Biotherapeutics (acquired in December 2020 by AnGes, Inc.) she established the company’s US operations and capital market footprint for IPO preparedness and completed the M & A transaction. During her time at Abeona Therapeutics, she operated in multiple senior executive roles including CFO and Principal Financial Officer. Earlier in her career, she drove internal capital markets strategy at Relmada Therapeutics, Inc., and held senior executive roles within biotechnology venture fund SCO Capital Partners.

Christine began her career in the financial services industry where she was instrumental in advising clients on transaction considerations and formulating effective US public listing and financing strategies.